search
Back to results

HYPoxaEmic Respiratory Failure and Awake Prone Ventilation (Hyper-AP)

Primary Purpose

Respiratory Failure, Hypoxemia

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Awake prone position (APP)
Sponsored by
Vilnius University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Failure focused on measuring Awake prone, Respiratory failure, ARDS, Hypoxaemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adult patients admitted to intensive care unit for acute hypoxemic respiratory failure. Acute hypoxemic respiratory failure is defined by respiratory rate ≥25 breaths/min, and partial pressure of oxygen in the arterial blood (PaO2)/fraction of inspired oxygen (FiO2) ≤300 mm Hg or oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio <235 while spontaneously breathing under standard oxygen with oxygen flow rate of at least 10 L/min, high flow oxygen therapy or non-invasive ventilation. For patients under standard oxygen, FiO2 is calculated according to the following formula: FiO2=0.21 + 0.03 per litre of supplemental oxygen. Informed consent Exclusion Criteria: impaired consciousness - Glasgow coma score <14; inability to cooperate or prone position intolerance; immediate indications for endotracheal intubation; patients with do-not-intubate order at time of inclusion; patients with contraindication to high flow oxygen therapy (HFOT) or non-invasive ventilation (NIV); Partial pressure of carbon dioxide (PaCO2) above 50 mm Hg and quantitative measure of the acidity (pH) <7,3; vasopressor dose >0.3 µg/kg/min of norepinephrine-equivalent to maintain systolic blood pressure >90 mmHg; Covid-19 positive

Sites / Locations

  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
  • Republican Vilnius University Hospital
  • Vilnius University Hospital Santaros KlinikosRecruiting
  • Barking, Havering and Redbridge University Hospitals NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

APP group

Control group

Arm Description

Awake prone position (APP) for 4 or more hours per day in addition to standard care for the first 72 hours from randomisation. After the initial period, use of APP is at discretion of the treating clinician. Awake prone can be discontinued earlier if patients meets pre-specified criteria of sustained improvement.

Standard care excluding APP

Outcomes

Primary Outcome Measures

Rate of endotracheal intubation
Incidence of endotracheal intubation in both groups

Secondary Outcome Measures

Mortality
Mortality during intensive care unit stay, in hospital, at day 90 and at 1 year
Duration of mechanical ventilation
Total number of mechanical ventilation days from endotracheal intubation to discharge from intensive care unit
Length of intensive care unit and hospital stay
Total cumulative number of days spent in intensive care unit and hospital
One year mortality
Incidence or death during one year of randomisation
Health related quality of life
Heath related quality of life assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) one year of randomisation

Full Information

First Posted
July 13, 2023
Last Updated
August 4, 2023
Sponsor
Vilnius University
Collaborators
Vilnius University Hospital Santaros Klinikos
search

1. Study Identification

Unique Protocol Identification Number
NCT05990101
Brief Title
HYPoxaEmic Respiratory Failure and Awake Prone Ventilation
Acronym
Hyper-AP
Official Title
HYPoxaEmic Respiratory Failure and Awake Prone Ventilation
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 12, 2023 (Actual)
Primary Completion Date
August 1, 2026 (Anticipated)
Study Completion Date
September 1, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vilnius University
Collaborators
Vilnius University Hospital Santaros Klinikos

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this prospective multi-centre randomised controlled trial is to determine if addition of awake prone positioning to standard oxygen, high flow oxygen therapy and non-invasive ventilation may reduce the rates of endotracheal intubation and mechanical ventilation.
Detailed Description
Effectiveness of prone position in mechanically ventilated patients was investigated extensively. During the Covid-19 pandemic a sudden increase in cases of acute respiratory failure, resulted in renewed interest and numerous studies on applying this concept in spontaneously breathing patients and using this in conjunction with less invasive respiratory support. However, evidence form the Covid-19 trials may not be directly extrapolated to other acute respiratory distress causes (for example bacterial pneumonia) as pathology of lung injury is distinctly different. Even though first reports of awake prone positioning were published nearly 30 years ago, but to date there are no prospective randomised trials in adult population treated for acute lung injury unrelated to Covid-19. Existing publications range from case reports (lung transplantation and drowning cases) to small feasibility trials involving 15-20 patients and also neonatal and paediatric populations. Considering that patients with acute lung injury constitute a significant proportion of routine intensive care unit population, results of this study would be highly relevant for the daily practice in intensive care medicine.We are aiming to conduct a prospective multi-centre randomised controlled trial comparing standard care alone with awake prone positioning and standard care in spontaneously breathing patients admitted to Intensive or Intermediate Care Units for acute non-Covid-19 hypoxemic respiratory failure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Failure, Hypoxemia
Keywords
Awake prone, Respiratory failure, ARDS, Hypoxaemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be allocated to the awake prone or standard care groups on a 1:1 ratio.
Masking
InvestigatorOutcomes Assessor
Masking Description
By the nature of the awake prone intervention, it will not be possible to blind clinicians; however, interventions will be blinded to data analysts and outcome assessors.
Allocation
Randomized
Enrollment
262 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
APP group
Arm Type
Experimental
Arm Description
Awake prone position (APP) for 4 or more hours per day in addition to standard care for the first 72 hours from randomisation. After the initial period, use of APP is at discretion of the treating clinician. Awake prone can be discontinued earlier if patients meets pre-specified criteria of sustained improvement.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Standard care excluding APP
Intervention Type
Behavioral
Intervention Name(s)
Awake prone position (APP)
Intervention Description
Awake prone position for 4 or more hours per day for the first 72 hours following randomisation.
Primary Outcome Measure Information:
Title
Rate of endotracheal intubation
Description
Incidence of endotracheal intubation in both groups
Time Frame
Within 30 days of randomisation
Secondary Outcome Measure Information:
Title
Mortality
Description
Mortality during intensive care unit stay, in hospital, at day 90 and at 1 year
Time Frame
Within 1 year of randomisation
Title
Duration of mechanical ventilation
Description
Total number of mechanical ventilation days from endotracheal intubation to discharge from intensive care unit
Time Frame
Within 30 days of randomisation
Title
Length of intensive care unit and hospital stay
Description
Total cumulative number of days spent in intensive care unit and hospital
Time Frame
Within 30 days of randomisation
Title
One year mortality
Description
Incidence or death during one year of randomisation
Time Frame
Within 1 year of randomisation
Title
Health related quality of life
Description
Heath related quality of life assessed by Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) one year of randomisation
Time Frame
Within 1 year of randomisation
Other Pre-specified Outcome Measures:
Title
Tolerance of awake prone positioning
Description
Proportion of patients in the intervention group completing at least 4 hours per day of awake prone positioning and number of awake prone hours per day
Time Frame
Within 72 hours of randomisation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients admitted to intensive care unit for acute hypoxemic respiratory failure. Acute hypoxemic respiratory failure is defined by respiratory rate ≥25 breaths/min, and partial pressure of oxygen in the arterial blood (PaO2)/fraction of inspired oxygen (FiO2) ≤300 mm Hg or oxygen saturation (SpO2)/fraction of inspired oxygen (FiO2) ratio <235 while spontaneously breathing under standard oxygen with oxygen flow rate of at least 10 L/min, high flow oxygen therapy or non-invasive ventilation. For patients under standard oxygen, FiO2 is calculated according to the following formula: FiO2=0.21 + 0.03 per litre of supplemental oxygen. Informed consent Exclusion Criteria: impaired consciousness - Glasgow coma score <14; inability to cooperate or prone position intolerance; immediate indications for endotracheal intubation; patients with do-not-intubate order at time of inclusion; patients with contraindication to high flow oxygen therapy (HFOT) or non-invasive ventilation (NIV); Partial pressure of carbon dioxide (PaCO2) above 50 mm Hg and quantitative measure of the acidity (pH) <7,3; vasopressor dose >0.3 µg/kg/min of norepinephrine-equivalent to maintain systolic blood pressure >90 mmHg; Covid-19 positive
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tomas Jovaisa, Prof
Phone
+37062697567
Email
tomas.jovaisa@santa.lt
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ieva Jovaisiene, Dr
Organizational Affiliation
Vilnius University Hospital Santaros Klinikos
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mandeep K Phull, Dr
Organizational Affiliation
Barking, Havering and Redbridge University Hospitals NHS Trust
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tomas Jovaisa, Prof
Organizational Affiliation
Vilnius University Hospital Santaros Klinikos
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital of Lithuanian University of Health Sciences Kaunas Clinics
City
Kaunas
Country
Lithuania
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomas Tamosuitis, Dr
Phone
+37068780950
Email
Tomas.Tamosuitis@kaunoklinikos.lt
Facility Name
Republican Vilnius University Hospital
City
Vilnius
ZIP/Postal Code
04130
Country
Lithuania
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Saulius Vosylius, Prof
Email
saulius.vosylius@gmail.com
Facility Name
Vilnius University Hospital Santaros Klinikos
City
Vilnius
Country
Lithuania
Individual Site Status
Recruiting
Facility Name
Barking, Havering and Redbridge University Hospitals NHS Trust
City
London
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mandeep K Phull, Dr
Email
mandeep.phull@nhs.net

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

HYPoxaEmic Respiratory Failure and Awake Prone Ventilation

We'll reach out to this number within 24 hrs